1. ALLA AKTIER
  2. NYHETER
  3. MAGLE CHEMOSWED

Magle Chemoswed

Nyheter Magle Chemoswed Nyheter alla bolag

Magle Chemoswed Holding AB (PUBL) – Publishes Full Year Report 2023 and Board’s Initial Proposal for Paying Dividends

MAR

Magle Chemoswed Holding AB (publ), an established innovation-led healthcare group with proven growth through risk diversification and focus on high-value revenue streams, today publishes the interim report for the fourth quarter of 2023 and the full year 2023. In conjunction with the Q4 and Full Year 2023 report, the Board of Directors has proposed to pay a dividend of SEK 0.35 to the shareholders for the fiscal year 2023. The detailed dividend proposal will be put forward by the Board in connection with the notice of the Annual General Meeting which is then subject to approval from the Annual General Meeting taking place on the 25th of April 2024.

OCTOBER – DECEMBER 2023

• Net sales amounted to 57.4 MSEK (45.9).

• EBITDA equalled 9.3 MSEK (6.2).

• Operating profit (EBIT) is 5.9 MSEK (3.2).

• Profit after tax amounted to 4.1 MSEK (0.6).

• Earnings per share SEK 0,4 (0,1) per share

JANUARY – DECEMBER 2023

• Net sales amounted to 170.4 MSEK (145.7).

• EBITDA equalled 31.1 MSEK (25.8).

• Operating profit (EBIT) is 18.0 MSEK (12.8).

• Profit after tax amounted to 12.2 MSEK (9.1).

• Earnings per share SEK 1,1 (0,8) per share.

Justin Pierce, CEO of Magle Chemoswed Holding AB, commented, “The full year of 2023 marked another milestone in our journey of growth and innovation. With significant revenue growth, strategic expansions, and pioneering DSM products and pipeline, we’re setting new standards in healthcare.

EVENTS DURING THE REPORTING PERIOD

• Automated fill and finish line investment closed.

• Barbara Willkomm appointed as the Director of Human Resources.

• A subsidiary, Magle Chemoswed LLC, has been registered in Delaware, USA.

EVENTS AFTER THE REPORTING PERIOD

• Initiated U.S. registration process for EmboCept®S

• The Board of Directors proposes a dividend of 0,35 SEK per share for the fiscal year.

• The detailed dividend proposal will be published in connection with the notice of the Annual General Meeting.

The full report can be downloaded at https://maglegroup.com/financial-reports/

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on www.maglechemoswed.com and https://maglegroup.com/ and www.maglepharmacept.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-16 08:30 CET.

Attachments

Year End Report Q4 2023

Datum 2024-02-16, kl 08:30
Källa MFN
Bifogade filer
Year End Report Q4 2023
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!